What did the results show in the trial evaluating intradermal response of the sanofi H5N1 vaccine?
All dose regimens of inactivated influenza A/H5N1 vaccine administered intradermally and intramuscularly were safe and well tolerated for all study participants. It was concluded that at the doses tested there was no clear advantage with regard to immunogenicity of intradermal administration when compared with intramuscular administration. Additional studies of H5N1 vaccine delivery are under consideration.
